Larimar Therapeutics Inc Total Liabilities
Larimar Therapeutics Inc total liabilities. Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has total liabilities worth $37.92 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Larimar Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Larimar Therapeutics Inc (2012–2025)
Total liabilities of Larimar Therapeutics Inc from 2012 to 2025. This chart illustrates how Larimar Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore LRMR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Larimar Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Larimar Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
China | CN¥275.07 Million |
|
Richmond Mutual Bancorporation Inc
NASDAQ:RMBI
|
USA | $1.40 Billion |
|
Lanzhou Zhuangyuan Pasture Co Ltd
SHE:002910
|
China | CN¥1.24 Billion |
|
Somany Ceramics Limited
NSE:SOMANYCERA
|
India | Rs10.41 Billion |
|
Empresas Gasco S.A
SN:GASCO
|
Chile | CL$625.17 Billion |
|
Chang Chun Eurasia Group Co Ltd
SHG:600697
|
China | CN¥15.49 Billion |
|
Better Home & Finance Holding Company
NASDAQ:BETR
|
USA | $1.48 Billion |
|
Fujian Sanmu Group Co Ltd
SHE:000632
|
China | CN¥7.98 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Larimar Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Larimar Therapeutics Inc.
Liquidity & Leverage Metrics
Larimar Therapeutics Inc Total Liabilities Ratios Explained
Larimar Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Larimar Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Larimar Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $67.76 Million | +138.47% |
| 2024-12-31 | $28.41 Million | +99.88% |
| 2023-12-31 | $14.21 Million | -8.30% |
| 2022-12-31 | $15.50 Million | +8.76% |
| 2021-12-31 | $14.25 Million | -4.94% |
| 2020-12-31 | $14.99 Million | +154.35% |
| 2019-12-31 | $5.89 Million | -79.31% |
| 2018-12-31 | $28.49 Million | +4.39% |
| 2017-12-31 | $27.29 Million | +175.85% |
| 2016-12-31 | $9.89 Million | -50.52% |
| 2015-12-31 | $20.00 Million | +52.90% |
| 2014-12-31 | $13.08 Million | +348.64% |
| 2013-12-31 | $2.92 Million | -0.51% |
| 2012-12-31 | $2.93 Million | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.